Study of lenacapavir for HIV treatment in France
Treatments studied
Part of Infections clinical trials.
This study looks at how well lenacapavir works when added to a personalized HIV treatment plan. If you have HIV and received lenacapavir as your first dose between June 2023 and June 2024, this research may help understand its real-world effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have HIV-1 (not HIV-2)
- You received your first dose of lenacapavir (by mouth or injection) between June 20, 2023 and June 30, 2024
- You took lenacapavir together with an optimized background regimen (a personalized mix of other HIV medicines)
- You did not refuse to allow your medical data to be collected and used for this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying a two-drug combination (cabotegravir and lenacapavir) given as long-acting shots for people with HIV. If you are already taking or about to start this combination, your doctor may invite you to join so researchers can track how well it works over time.
This trial tests a long-acting injectable form of HIV prevention (cabotegravir) vs. continuing daily PrEP pills. It is for cisgender men in France who have sex with men and have already been using PrEP for at least 6 months.
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
This trial tests whether adding a new long-acting drug, lenacapavir, to your current HIV treatment can reduce the hidden HIV that remains in your body even when standard treatment keeps the virus undetectable. The goal is to see if this can lead to better control of HIV over time.
This study offers a new injectable medication called lenacapavir to prevent HIV. It is for people who are HIV-negative and sexually active, and want to try a long-acting injection instead of daily pills.
Hear when a new HIV I Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.